IXICO plc Director's Dealings
4 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 3 February 2016 that, on the same day, Dr Andrew Richards, Non-Executive Chairman of the Company, purchased 45,899 Ordinary Shares of 1p each in IXICO at a price of 32.68p pence per Ordinary Share through his self-invested pension plan ("SIPP"), of which he is the sole beneficiary.
As a consequence of this share purchase, Dr Andrew Richards is beneficially interested in 76,099 Ordinary Shares representing 0.29% of the Company's issued share capital.
Derek Hill, CEO
Susan Lowther, CFO
+44 20 3763 7499
Peel Hunt LLP (Nominated Adviser and Broker)
James Steel / Oliver Jackson
+44 20 7418 8900
Daniel Stewart & Company (Joint Broker)
Martin Lampshire / David Coffman
+44 207 776 6550
FTI Consulting Limited (Investor Relations)
Simon Conway / Mo Noonan / Matthew Moss
+44 20 3727 1000
Notes to Editors
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.